Stem Cell Therapy for Diabetic Peripheral Neuropathy: Pilot Data, Schwann Cell Mechanisms, and the Exosome Shift

Two 2026 systematic reviews, a Schwann cell mechanism study, and the first powered RCT in diabetic peripheral neuropathy — what clinicians need to know about MSC and exosome therapy for DPN.

Читать далее...

Mesenchymal Stem Cell Therapy in Cervical Cancer: What the 2026 Evidence Shows

A 2026 systematic review found 14 studies of mesenchymal stem cells in cervical cancer, with contradictory results and no study controlling for HPV genotype. Here is what the evidence actually shows.

Читать далее...

Glycocalyx-Edited MSC Therapy for Advanced Osteoporosis: First-in-Human Trial Results Published in Cell

The first-in-human trial of glycocalyx-edited autologous MSCs shows that engineering bone homing via sLeX expression reduces fragility fractures and increases bone density in advanced osteoporosis patients, with five-plus years of safety data and no serious adverse events.

Читать далее...

MSC Therapy for Traumatic Brain Injury: Phase 1/2a Results Show Reduced Brain Inflammation and Clinical Improvement

The Cox et al. Phase 1/2a trial in Brain (2026) demonstrates that autologous adipose-derived MSCs reduce brain immune cell density and improve depression, fatigue, and pain in chronic TBI patients.

Читать далее...

Stem Cell Therapy for Hair Loss in 2026: What the Science Actually Shows

From MSC secretome to exosome injections and next-gen PRP alternatives, here is what 2026 research says about regenerative hair loss treatments — and who they work best for.

Читать далее...

How Sleep Protects Your Stem Cells — and What Happens When You Don’t Get Enough

New 2026 research shows that uninterrupted sleep reprograms stem cells and suppresses mutant clone expansion. Here's what the science says about protecting your body's repair cells while you rest.

Читать далее...

MSC Therapy for Alzheimer’s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes

Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.

Читать далее...
Вершина